Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 141
- 试验地点
- 12
- 主要终点
- overall survival
研究概览
简要总结
The prognosis of patients with newly diagnosed glioblastoma is dismal despite recent therapeutic improvements Using standard therapy with temozolomide (TMZ) and radiotherapy (60 Gy), the median overall survival time (mOS) is 14.6 months (Stupp et al., 2005). Since in a previous non-randomized bicentric phase II trial, primary combination chemotherapy with lomustine (CCNU) and TMZ was highly effective (mOS 23 months; UKT-03 trial; Herrlinger et al., 2006; Glas et al., 2009) the proposed trial further investigates the efficacy of CCNU/TMZ in a randomized multicenter phase III setting against standard therapy. In case the projected phase III trial confirms the phase II data, CCNU/TMZ combination would be significantly better than TMZ monotherapy and would thus be the new standard treatment for newly diagnosed GBM patients with a methylated MGMT promotor. Thus, this trial has the potential to profoundly change the standard therapy of this most aggressive brain tumor. Since in the previous trial only patients with a methylated MGMT (mMGMT) promoter had a benefit from CCNU/TMZ (mOS in the mMGMT group 34 months, in the non-mMGMT group 12.5 months; Glas et al., 2009) while patients with a non-methylated MGMT did not have any benefit, the trial is restricted to mMGMT patients.The CeTeG trial randomizes in a 1:1 fashion newly diagnosed GBM patients (18-70 years) for either standard TMZ therapy (concomitant and 6 courses à 4 weeks of adjuvant TMZ therapy) or experimental CCNU/TMZ therapy (6 courses à 6 weeks). Both arms include standard radiotherapy (RT) of the tumor site (30 x 2 Gy). Assuming that CCNU/TMZ therapy increases the median overall survival (mOS) from 48.9% (standard TMZ) to 70% (CCNU/TMZ; 75% in the previous phase II trial, Glas et al., 2009), 2 x 68 patients have to be accrued. Patients will be accrued over 24 months and each patient will be followed for at least 24 months adding up to a total minimal duration of the time from first patient in until the end of the follow-up time of 48 months. The primary endpoint is overall survival; secondary endpoints include progression-free survival, response rate, acute and late toxicity, and quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •written informed consent
- •patients have to be in a cognitive state that allows them to understand the rationale and necessity of study therapy and procedures.
- •newly diagnosed histologically proven GBM or gliosarcoma WHO Grad IV
- •methylated MGMT promoter in the tumor
- •estimated life expectancy of at least 12 weeks
- •Karnofsky Performance Score (KPS) ≥ 70%
- •patient compliance and geographic proximity that allow adequate follow up
- •male and female patients with reproductive potential must use an approved contraceptive method
- •pre-menopausal female patients with childbearing potential: a negative serum pregnancy test must be obtained prior to treatment start
- •Adequate organ function as described below:
- •Adequate bone marrow reserve:
- •white blood cell (WBC) count > 3000/µl, granulocyte count >1500/µl, platelets > 100000/µl, haemoglobin ≥ 10 g/dl Adequate liver function bilirubin < 1.5 times above upper limit of normal range (ULN), ALT and AST < 3 times ULN creatinine < 1.5 times ULN
- •Adequate blood clotting:
- •PT and PTT within normal limits Negative HIV test
排除标准
- •prior malignancy
- •prior chemotherapy
- •prior radiotherapy to the brain
- •concurrent administration of any other anti-tumor therapy
- •allergy or other intolerability of temozolomide, CCNU, dacarbazine or other nitrosourea derivatives
- •unable to undergo MRI
- •past medical history of diseases with poor prognosis
- •known HIV infection, active Hepatitis B or C infection
- •any active infection
- •female patients that are pregnant or breastfeeding
- •patients with reproductive potential who do not accept to use contraception
- •treatment in another clinical trial
- •any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up scheduled visits (at the discretion of investigator)
研究组 & 干预措施
lomustine (CCNU) + temozolomide (TMZ) and radiotherapy
60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
干预措施: Temozolomide and lomustine (Drug)
temozolomide and radiotherapy
60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
干预措施: Temozolomide (Drug)
结局指标
主要结局
overall survival
时间窗: after follow up (4 years)
次要结局
- best response rate determined by MRI(after follow up (4 years))
- frequency of delay of the next Lomustine/Temozolomide or Temozolomide course(during treatment period (2 years))
- progression free survival(after follow up (4 years))
- acute toxicity during radiotherapy and chemotherapy according to CTC AE V3.0(during treatment period (2 years))
- quality of life(including follow up (4 years))
- Evaluation of late neurotoxicity(after follow up (4 years))
研究者
Ulrich Herrlinger
Head, Division of Clinical Neurooncology
University Hospital, Bonn